PDCD1 and gastric cancer: The ATTRACTION-2 trial, the first randomized, double-blind, placebo-controlled, phase III study, demonstrated the efficacy and safety of nivolumab, a humanized anti-PD-1 monoclonal antibody, as a third- or later-line treatment for patients with advanced gastric cancer (AGC) (11).